Expand ATAI Menu
ATAI MENU

ATAI Latest Press Releases

-- July 28, 2026 --

ATAI Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Proposed Sale of AtaiBeckley to Eli Lilly Globe Newswire 9:26 AM

-- July 21, 2026 --

Are PSNL, LXP, DSGR, ATAI Obtaining Fair Deals for their Shareholders? PRNewswire 2:50 PM

-- July 17, 2026 --

AtaiBeckley Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of AtaiBeckley Inc. - ATAI Business Wire 2:57 PM

-- July 16, 2026 --

Are ATAI, FHB, PATK Obtaining Fair Deals for their Shareholders? PRNewswire 6:17 PM
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of AtaiBeckley Inc. (NASDAQ: ATAI) PRNewswire 2:23 PM
Shareholder Alert: Ademi LLP investigates whether AtaiBeckley Inc. is obtaining a Fair Price for Public Shareholders PRNewswire 12:03 PM
Halper Sadeh LLC is Investigating Whether ATAI, CCRN, NUVL are Obtaining Fair Deals for their Shareholders Globe Newswire 11:41 AM
ATAI Stock Alert: Halper Sadeh LLC is Investigating Whether AtaiBeckley Inc. is Obtaining a Fair Price for its Shareholders Business Wire 9:30 AM
Lilly to acquire AtaiBeckley to advance therapies for treatment-resistant depression and other mental health conditions PRNewswire 6:45 AM

-- July 6, 2026 --

AtaiBeckley Doses Last Patient in VLS-01 Phase 2b TRD Study; Plans Phase 3 in Major Depressive Disorder Globe Newswire 6:00 AM

-- June 25, 2026 --

AtaiBeckley to Join the Russell Indexes, Expanding Visibility Across U.S. Equity Markets Globe Newswire 6:00 AM

-- May 28, 2026 --

AtaiBeckley Launches Patient Impact Grant Program for Mental Health Non-Profit Organizations Globe Newswire 9:00 AM

-- May 27, 2026 --

AtaiBeckley to Participate in Upcoming Investor Conferences in June 2026 Globe Newswire 6:00 AM

-- May 12, 2026 --

AtaiBeckley Reports First Quarter 2026 Financial Results and Provides Program and Business Update Globe Newswire 8:00 AM

-- April 27, 2026 --

AtaiBeckley and PsyPAN Receive a Silver Award in 2026 Patient Participant Index, Reflecting Ongoing Commitment to Participant-Informed Research Globe Newswire 4:05 AM

-- April 22, 2026 --

AtaiBeckley Announces Additional Phase 2a Results for EMP-01 (oral R-MDMA) Showing Large and Consistent Improvements in Social Anxiety Disorder Globe Newswire 6:00 AM

-- April 14, 2026 --

AtaiBeckley to Participate in Upcoming Needham Healthcare Conferences Globe Newswire 6:00 AM

-- April 8, 2026 --

AtaiBeckley's BPL-003 Shows Rapid, Durable Antidepressant Response in Treatment-Resistant Depression Patients on SSRIs; Phase 2a Data Published in CNS Drugs Globe Newswire 6:00 AM

-- March 24, 2026 --

AtaiBeckley Joins $3 Trillion CRSP Index and S&P Benchmark Indices Adding Mandatory Passive Fund Ownership to Phase 3 Pipeline Catalyst Globe Newswire 6:00 AM

-- March 17, 2026 --

BPL-003 Demonstrates Rapid and Durable Antidepressant Effects in Treatment-Resistant Depression; Phase 2a Data Published in Journal of Psychopharmacology; Phase 3 Program on Track for Q2 2026 Initiation Globe Newswire 6:00 AM

-- March 10, 2026 --

BPL-003 Phase 3 Program Initiation on Track for Q2 2026 Following Successful FDA End-of-Phase 2 Meeting; AtaiBeckley Highlights Key Pipeline Milestones at 2026 Investor Day Globe Newswire 6:00 AM

-- March 6, 2026 --

AtaiBeckley Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business and Clinical Update Globe Newswire 7:00 AM

-- March 3, 2026 --

AtaiBeckley Announces Successful End-of-Phase 2 Meeting for BPL-003 in Treatment-Resistant Depression Globe Newswire 7:00 AM
Market Data Delayed 15 Minutes